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Regulatory B cells (Breg) have immune suppres-
sive functions in various autoimmune/inflammation
models and diseases and are found to be enriched
in diverse B cell subsets. The lack of a unique marker
or set of markers efficiently identifying Breg cells im-
pedes detailed investigation into their origin, devel-
opment, and immunological roles. Here, we perform
transcriptome analysis of IL-10-expressing B cells
to identify key regulators for Breg biogenesis and
function and identify CD9, a tetraspanin-family trans-
membrane protein, as a key surface marker for most
mouse IL-10+ B cells and their progenitors. CD9
plays a role in the suppressive function of IL-10+ B
cells in ex vivo T cell proliferation assays through a
mechanism that is dependent upon B/T cell interac-
tions. CD9+ B cells also demonstrate inhibition of
Th1-mediated contact hypersensitivity in an in vivo
model system. Taken together, our findings implicate
CD9 in the immunosuppressive activity of regulatory
B cells.
INTRODUCTION
In addition to the normal antibody generating function, a subset
of B cells, known as regulatory B cells (Bregs), can suppress
several immune processes including allergy, autoimmunity, anti-
gen presentation, and pro-inflammatory cytokine production
(DiLillo et al., 2010; Mauri and Bosma, 2012). Breg regulation
has been demonstrated in various autoimmune- and inflamma-
tion-induced mouse models (Mauri et al., 2003; Sattler et al.,
2014; Yanaba et al., 2008; Yoshizaki et al., 2012), and aberrant
regulation of Bregs has been reported in human diseases such
as systemic lupus erythematosus (Blair et al., 2010), allergies
(van de Veen et al., 2013), and autoimmune diseases and disor-
ders (Kalampokis et al., 2013).
Bregs are found enriched in phenotypically diverse B cell sub-
sets. In mice, reported markers of Bregs include CD1d, CD5,1110 Cell Reports 13, 1110–1117, November 10, 2015 ª2015 The AuCD19, CD11b, CD21, CD23, CD32b, CD138, immunoglobulin
M (IgM), IgD, TIM-1, and CX3CR1 (Ding et al., 2011; Mauri and
Bosma, 2012; Shen et al., 2014; Stolp et al., 2014; Yanaba
et al., 2008), whereas in humans Bregs markers have been
reported to include CD1d, CD5, CD19, CD24, CD25, CD27,
CD38, CD48, CD71, CD73, CD148, and IgM (Iwata et al., 2011;
Lindner et al., 2013; Mauri and Bosma, 2012; Stolp et al., 2014;
van de Veen et al., 2013).Mice and humans thus possess distinct
sets of Breg markers, and there is a scarcity of unique markers
that would exclusively and exhaustively identify Breg cells.
It has been suggested that signals triggering theBcell receptor
(BCR)—CD40 ligation and Toll-like receptor engagement—may
play important roles in the development and/or activation of
Bregs (Blair et al., 2009; Lampropoulou et al., 2008).Nonetheless,
the precise cellular origins of Bregs remain unknown, as do their
developmental pathways. It has been proposed that Bregs may
derive from a unique progenitor (Yanaba et al., 2009) or differen-
tiate fromdistinct subsets of B cells triggeredby aparticular stim-
ulus (Zhang, 2013). These twohypotheses are notmutually exclu-
sive but need to be further investigated. Isolating uniquemarkers
identifying all Bregsmay be a crucial first step in determining their
ontology. In this study, we have investigated the transcriptome of
B10 cells, an antigen-specific CD1dhiCD5+CD19+IL-10competent
Breg cell (DiLillo et al., 2010; Yanaba et al., 2008) and identified
CD9 as an important B10 cell marker.
RESULTS
Identification of Differentially Expressed mRNAs,
miRNAs, and lncRNAs in B10 Cells
We sorted B10+ cells (CD1dhiCD5+CD19+IL-10+) and B10– cells
(CD1d–CD5–CD19+IL-10–) from mouse splenic B cells (Fig-
ure S1A) for RNA sequencing (RNA-seq) and microarray anal-
ysis. Together with the qRT-PCR results, the mapped reads of
published B10 cellular markers, common B cell markers, and
the lack of T cell markers, demonstrate high quality of the
RNA-seq data (Figures S1B–S1D). We analyzed the rank change
(RC) and fold change (FC) of mRNAs (Figure 1A; Table S1) be-
tween B10+ and B10– cells and generated a highly reliable list
of differentially expressed mRNAs (Figure 1B). 55 mRNAs over-
lap between the top 100-fold change mRNAs and the top 100thors
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Figure 1. Differentially Expressed mRNA, lncRNA, and miRNA in B10 Cells
(A) Overall changes of gene expression level between B10+ cells (CD1dhiCD5+CD19+IL-10+) and B10– cells (CD1d–CD5–CD19+IL-10–) determined by RNA-seq.
*The number of mRNAs after removing mRNAs with FPKM <1 in both B10+ and B10– cells in any batch, and mRNA with FPKM = 0 in any sample. See Sup-
plemental Experimental Procedures for more information.
(B) The distribution of genes in the top iFC and iRC groups. The gene list is summarized in Table S1.
(C) The rank changes of the 55 genes existing in both the top 100 iFC and the top 100 iRC. IL-10 is ranked first in both rank lists.
(D) Fold change of the 44 novel lncRNAs identified from the lncRNA database (Pefanis et al., 2014, 2015). The lncRNAs are nomenclatured according to the gene
closest to the lncRNA coding region.
(E) General changes of miRNA expression levels between B10+ cells and B10– cells as determined by microarray analysis. Max signal, the maximum signal in all
four samples of the two batches.
(F) The expression changes of the miRNAs with iFCR3 and max signalR32.
Please also see Figures S1 and S2 and Tables S1, S2, and S3.rank change mRNAs, and Il10 is ranked first by both methods
(Figure 1C). We provide the full list of 273 differentially expressed
mRNAs in Table S1.
Most of the mammalian genome has the potential to express
various types of non-coding RNAs, ranging from miRNAs to
lncRNAs (Fatica and Bozzoni, 2014; Hausser and Zavolan,
2014). As the RNA exosome complex is implicated in ncRNA
half-life, we cross-referenced our database of lncRNAs isolated
from RNA exosome knockout B cells (Pefanis et al., 2014, 2015)
and found 38 upregulated lncRNAs and six downregulated
lncRNAs from a library derived from B10+ B cells (Figure 1D;
Table S1). In addition, by microarray analysis we compared the
miRNA expression levels between B10+ and B10– cells. General
changes in miRNA expression levels are summarized in Fig-Cell Repure 1E; the expression changes of the miRNAs with iFC R3
and max signal R32 are shown in Figure 1F. Table S1 lists 77
differentially expressed miRNAs in B10+ cells.
mRNA/miRNA Pairing, Prediction of Upstream
Regulators, and Gene Ontology Term Enrichment
Analysis
Using the Ingenuity Pathway Analysis (IPA) program (Kra¨mer
et al., 2014), we analyzed mRNA/miRNA pairing and predicted
upstream regulators from the 273 differentially expressed
mRNAs and the 77 differentially expressed miRNAs. We find
there are 31 miRNAs targeting 134 mRNAs (Table S2). Notably,
there are 56 upstream regulators differentially expressed be-
tween B10+ and B10– cells in the total of 1,758 predictedorts 13, 1110–1117, November 10, 2015 ª2015 The Authors 1111
upstream regulators (Table S3), and four of the 56 are transcrip-
tion regulators (STAT1, CDKN2A, MYB, and PRDM1).
Five interconnected stages and processes correlate tightly
with Breg biogenesis and function (outlined in Figure S2). Based
on the reported functions and features of various cell types in the
literature, we divided the differentially expressed upstream reg-
ulators into eight groups by the IPA program and in Figure S2
predict the potential involvement of each group in the five stages
according to gene ontology term enrichment analysis (Table S3).
Of the upstream regulators, IL-10, IL-33, HAVCR1 (also named
TIM1), and CD5 have been reported to be important molecules
for Breg biogenesis and function (Ding et al., 2011; Sattler
et al., 2014; Shen et al., 2014; Yanaba et al., 2008; Yoshizaki
et al., 2012).
Comparison of Differentially Expressed mRNAs in B10
and Other Cell Subsets Suggests CD9 Is a Marker of
IL-10competent B Cells
Comparing the differentially expressed genes found in B10 cells
with those found in other B cell subsets might provide important
information on Breg origin and characterization. Based on data
sets generated via The Immunological Genome Project (https://
www.immgen.org/), differentially expressed genes were identi-
fied between B1a B cells and FO B cells derived from spleen or
peritoneal cavity, between B1a and B1b B cells from peritoneal
cavity, and between marginal zone (MZ) B cells and follicular
(FO) B cells from spleen (Table S4). The expression of numerous
differentially expressed genes in B10 cells undergoes similar
change regardless of whether the B1a cells are derived from
spleen, peritoneal cavity, or MZ B cells (Figure S3A). 19 genes
(underlined) including Actn1, Atxn1, Ccr6, Cd300lf, Cd9, Cfp,
Csf2rb, Ctla4, Emb, Fcer2a, Fcrl5, Nek2, Nrp2, Ptpn22, Spn,
Stom, Tbc1d9, Zfp318, and Zfp608 appear on at least three lists.
Cd9 and Ccr1 are the only two genes appearing on all four lists,
suggesting that CD9 andCCR1may be goodmarkers with which
to identify Bregs from different B cell subsets.
Screening of Unique Markers Found by
RNA-Seq Identifies CD9 as a Robust Marker of
IL-10competent B Cells
To find unique markers for Bregs, we examined surface expres-
sion levels of CD9, CCR1, and other proteins corresponding to
the main cluster of differentiation (CD) antigens that showed dif-
ferential mRNA expression levels in B10 cells (Figure 2A). As
shown in Figure 2B, IL-10+ B cells contain a higher percentage
of cells expressing certain markers than do IL-10– B cells upon
treatment with anti-CD40 antibody for 48 hr, consistent with
our RNA-seq data. Notably, the difference in CD9 expression be-
tween IL-10+ and IL-10– B cells at 48 hr is greater than that of any
other tested marker(s) as well as the cells at 5 hr without CD40
antibody stimulation (Figure 2C). Moreover, most IL-10+ B cells
are CD9 positive at both 5 hr (87.03% ± 1.22%) and 48 hr
(87.95% ± 1.25%). The same phenomenon was also found for
peritoneal cavity B cells (Figure 2E). As CD9 is also a marker of
all murine hematopoietic stem cells (Karlsson et al., 2013), an
important question is whether the IL-10+ B cells are derived
from CD9+ B cells, CD9– B cells, or both. To address this issue,
we sorted CD9+ and CD9– B cells from naive B cells, CD9–IL-10–1112 Cell Reports 13, 1110–1117, November 10, 2015 ª2015 The AuB cells, CD9+IL-10– B cells, and CD9+IL-10+ B cells from cells
treated with lipopolysaccharides (LPSs), phorbol 12-myristate
13-acetate (PMA), and ionomycin (LPI) for 5 hr (Figure 2F). The
sorted cells were cultured with CD40 antibody for 48 hr and
LPI plusmonensin (LPI+M)were added for the final 5 hr. Figure 2F
shows that the progenitors of IL-10competent B cells exist as CD9+
B cells. As CD9 is expressed in MZ B cells, B1 cells, and plasma
cells (Won and Kearney, 2002), we evaluated the expression of
CD9 and IL-10 in these cell populations (Figures S3C and
S3D). Although IL-10+ B cells are also enriched in MZ B cells
compared to FO B cells (around 30% of MZ-B cells are IL-10+,
while only around 5% of FO B cells are IL-10+ B cells), MZ B cells
only represent approximately 20% of total IL-10+ B cells, while
FO B cells represent 40% of total IL-10+ B cells. IL-10+ B cells
are indeed enriched in B1a and B1b cells compared to B2 cells.
More than 40% of B1 cells are IL-10+ B cells, and this population
represents more than 88% of total IL-10+ B cells. The IL-10+ B1
cells and IL-10+ MZ B cells are all enriched in CD9-expressing B
cells. Next, in mouse B10 cells we compared CD9 expression
with previously described markers CD1d, CD5, CD11b, CD21,
CD23, CD32b, CD138, CX3CR1, IgD, IgM, and TIM1 (Figure 3)
and further confirmed that CD9 is a surface marker for a variety
of mouse IL-10competent B cells.
Suppressive Function of CD19+ CD9+ B Cells
To check whether CD9+ B cells have immune regulatory
functions, we isolated CD19+CD9+ B cells and CD19+CD9– B
cells and co-cultured them with VPD450-stained CD4+ CD25–
T cells. CD9+ B cells suppressed T cell proliferation more effi-
ciently than CD9– B cells, based on VPD450 dilution in co-culture
assays (B cell: T cell = 400:100) at both 48 and 72 hr (Figure 4A).
Interestingly, as shown in Figure 4B, blocking the CD9 moiety
with antibody impaired the suppression of T cell growth by
CD9+ B cells, suggesting that CD9 plays an important role in im-
mune suppressive function of B10 cells. We further checked
whether CD9 acts as a scavenger molecule for CD9+ B cell sup-
pressive activity by culturing T cells and CD9+/CD9– B cells in
separate compartments of a transwell plate. As shown in Fig-
ure 4C, CD9+ B cells show inhibitory effects on proliferation
of T cells, which are either separated from B cells by insert
(T cells in receiver well) or mixed with the CD9+ B cells in insert
(T cells in insert well). Additional interesting corollary conclusions
emerging from these experiments include (1) even without addi-
tion of CD40 antibody and LPS during the terminal 5 hr of culture
with PMA and ionomycin, a certain number of CD9+ B cells
secreted IL-10, while fewer of the CD9– B cells secreted IL-10
(Figure 4D) and (2) more CD9+ cells secreted IL-10 if the ratio
of T cells to B cells in the co-culture increased, suggesting that
IL-10 secretion by B cells may require interaction between B
cells and T cells. These observations suggest that CD9+ B cells
may require both cross-talk with T cells and secretion of IL-10
to eventually suppress CD4+ T cell proliferation. These observa-
tions have been modeled in Figure S4D and are discussed in
greater detail below.
To ascertain whether results obtained in ex vivo assays reca-
pitulate in vivo function, we adoptively transferred isolated CD9+
B cells and CD9– B cells into CD19/ mice to check the sup-
pressive function of CD9+ B cells on Th1-cell-mediated contactthors
Figure 2. IL-10competent B Cells and Their Progenitors Are Distinguished by CD9
(A–D) Screening markers for IL-10competent B cells identified by RNA-seq. (A) The mapped reads of differentially expressed CD antigens as well as CCR1
determined by RNA-seq on B10+ and B10– cells. (B and C) Representative expression of IL-10 and themolecules by total B cells (the dot plots), and expression of
the molecules on CD19+IL-10+ and CD19+IL-10– cells (the histogram plots) was determined by flow cytometry. The percentage population is shown for CD19+IL-
10+ cells. All B cells are enrichedwith CD19micro-beads and then treatedwith LPI+M for 5 hr (C) or CD40 antibody for 48 hr plus LPI+M for the terminal 5 hr (B). (D)
Statistical results of expression of various molecules on IL-10+ or IL-10– B cells.
(E) Expression of IL-10 and CD9 on CD19+ B cells isolated from peritoneal cavity (PC) B cells or splenic (SP) B cells and treated with LPI+M for 5 hr or CD40
antibody for 48 hr followed by LPI+M for the terminal 5 hr. Two different CD9 antibodies were used. The bar graph shows the statistical frequency of subsets in
total or IL-10+ B cells.
(F) Expression change of IL-10 and CD9 on the indicated sorted cell subsets after incubation with CD40 antibody for 48 hr followed by LPI+M for the terminal 5 hr.
The bar graph shows the statistical frequency of IL-10+ in the sorted subsets. Cell subsets were sorted from naive B cells treatedwith (for IL-10 staining) or without
(for CD19 and CD9 staining only) LPI for 5 hr. Statistical data are represented as mean with SEM p value was obtained by multiple t test.
Please also see Figure S3 and Table S4.hypersensitivity. In comparison to CD19/ mice injected with
CD9– B cells, the ear thickness both of CD19/ mice injected
with CD9+ B cells and of WTmice injected with PBSwere thinner
throughout the whole process, and the differences were most
significant at 48 hr post oxazolone challenge. These observa-
tions provide evidence that CD9+ B cells possess immune regu-
latory function (Figure 4E).
Increased IL-10competent B Cells in a CD9/ Mouse
Model
To ascertain whether CD9 is important for IL-10 production or
B10 biogenesis, we employed flow cytometry to compare theCell Repexpression levels of the main markers reported for Bregs from
WT mice and CD9/ mice. Consistent with a previous report
(Cariappa et al., 2005), none of the checked markers was ex-
pressed at an appreciably different level on total B cells from
CD9/ and WT mice. Likewise, for IL-10+ B cells isolated from
CD9/ and WT mice, no major difference in the marker expres-
sion was noted. However, on IL-10+ B cells from CD9/ mice,
CD23 expression differed from the WT (Figure S4F). Further
analysis indicated that more MZ B cells and approximately twice
the number of IL-10competent B cells exist in CD9/ B cells
compared with WT (Figures 4F, S4F, and S4G), suggesting
that CD9 may play an important role in B10 maturation.orts 13, 1110–1117, November 10, 2015 ª2015 The Authors 1113
Figure 3. CD9 Is a Robust Surface Marker for Mouse IL-10competent B Cells
(A) Representative expression of IL-10, CD9, and other reported Breg markers on total, IL-10+, or IL-10– B cells stimulated with LPI+M for 5 hr or CD40 antibody
for 48 hr plus LPI+M for the terminal 5 hr. The frequency of cells expressing specific markers on IL-10+ B cells is shown in the histograms.
(B) The statistical frequency of subsets expressing specific markers on IL-10– or IL-10+ B cells. Statistical data are represented as mean with SEM.DISCUSSION
The phenotypic diversity found in Breg subsets makes the dis-
covery of Breg origin a difficult endeavor. Unique cell surface
markers, coupled with transcription factors, could provide
distinct signatures (Mauri and Bosma, 2012). In this study, we
profile the RNA expression of B10 cells, identify key upstream
regulators, and find CD9 as a novel functional marker of most
IL-10competent B cells and their progenitors. The identified unique
marker CD9 can separate B10 progenitors, IL-10+ B cells from
IL-10– B cells. Thus, the identification of CD9 allows the iden-
tification of IL-10+ B cells without stimulation of IL-10 secre-
tion, thereby providing a system to study unperturbed gene
expression profiles of Bregs and Breg progenitors. This is espe-
cially important since Breg transcription factor activity and
networks may otherwise be perturbed by stimulation with
LPS, PMA, and ionomycin. Accordingly, the CD9 marker may
assist in the identification of transcription factors driving Breg
differentiation.1114 Cell Reports 13, 1110–1117, November 10, 2015 ª2015 The AuIt remains unclear how and whether B10 cells regulate other
cells of the immune system and whether the regulation occurs
through direct cell-cell interaction or through the localized
expression and supply of cytokines (DiLillo et al., 2010; Mauri
and Blair, 2010). Ex vivo functional assay of CD19+CD9+ B cells
with CD9 blocking antibody demonstrated that CD9 is involved
in the suppressive function of CD19+CD9+ B cells (Figure 4B).
However, following interaction with CD4+ T cells in the insert of
the transwell plate, CD9+ B cells are able to suppress prolifera-
tion of T cells present in a physically separate receiver well of
the transwell plate (Figure 4C). Thus, it is possible that CD9
may facilitate communication of B10 cells with T cells leading
to secretion of IL-10 which then suppresses T cell proliferation
(modeled in Figure S4D). Further experiments, particularly with
CD9-conditional allele knockout mouse models, will be required
to establish the true nature of CD9’s function during B cell-medi-
ated immunosuppression. A separate but untested possibility
exists—that the regulatory function of CD19+CD9+ B cells results
from the release of CD9 containing exosomes, since mousethors
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Figure 4. CD9 Is Involved in B10 Function and Biogenesis
(A) Representative and statistical proliferation of T cells co-cultured for 48 and 72 hr at the indicated initial ratio with CD9+ or CD9– B cells. The statistical results are
normalized by the T cells co-cultured without B cells.
(B) Representative and statistical proliferation of T cells co-cultured for 72 hr at the indicated initial ratio with CD9+ or CD9– B cells in the presence of antibodies.
(C) Representative and statistical proliferation of T cells (1003 103) in the insert or in the receiver well of the transwell plate. The insert was added at the indicated
initial ratio with CD9+ or CD9– B cells as shown in the bottom cartoon and incubated for 72 hr.
(D) Statistical analysis of IL-10 production by CD9+ B cells and CD9– B cells treated with PMA, ionomycin, and monensinfor the terminal 5 hr of culture.
(A–D) CD9+ or CD9– B cells were sorted from CD19+ B cells treated with CD40 antibody and LPS for 5 hr. CD4+CD25– T cells were sorted from naive CD19– cells
and then stained by VPD450 before culturing in the plates pretreated with 5 mg/ml CD3e antibody. Medium was changed at 48 hr.
(E) Ear thickness change of CD19 knockout mice adoptively transferred with CD9+ B cells or CD9– B cells in an in vivo B cell functional analysis assay. WT and
CD19 KO mice injected with PBS were the controls for the experiment. The cells were sorted as described in Experimental Procedures.
(F) The frequency of MZB and FOB in total B cells or IL-10+ B cells and the frequency of IL-10+ B cells in total, FO, andMZB cells. Statistical data are represented
as mean with SEM p values were obtained by multiple t test.
Please also see Figure S4.exosomes contain an abundance of CD9 (The´ry et al., 1999)—
and the exosomes derived from mouse Tregs suppress patho-
genic T helper 1 cells (Okoye et al., 2014).
Human CD9+ B cells may not have functions similar to mouse
CD9+ B cells and may not represent most of the human IL-
10competent B cells because proteomic analysis of exosomes
from human B cells (Escola et al., 1998), lymphoma cells (Yao
et al., 2015), and other human cells (Hegmans et al., 2004)
did not identify CD9. Perhaps there is a CD9 equivalent devel-
opmental marker for B10 cells in humans, and it would be
insightful to investigate the full range of tetraspanin family pro-Cell Reptein expression on the surface of human IL-10+ B cells. Some
identified regulators—such as CD80, CD5, HAVCR1, and IL-
33—have been reported to be important Breg differentiation
and function factors. CD80/CD86, as well as Toll-like receptors
(TLRs) and CD40, are important co-stimulatory molecules
involved in B cell differentiation (Mann et al., 2007). CD5 is a
marker shared by many reported Breg subsets. HAVCR1 is a
co-stimulatory molecule enriched in IL-10 producing Breg cells
that can be induced by Havcr1 crosslinking using a Havcr1-
specific antibody (Ding et al., 2011). These are all worthy of
study, but the many regulators, including both protein factorsorts 13, 1110–1117, November 10, 2015 ª2015 The Authors 1115
and non-coding RNAs, we have reported here need to be stud-
ied further to determine their true biological potential in Breg
biology.
EXPERIMENTAL PROCEDURES
Mouse Strains and Spleens
C57BL/6J mice and CD19 knockout mice (B6.129P2(C)-Cd19tm1(cre)Cgn/J)
were purchased from The Jackson Laboratory. Spleens of CD9 knockout
mice (Miyado et al., 2000) and WT mice were obtained from the animal facility
of Osaka University Graduate School of Medicine in Japan. All animals were
handled in strict accordance with the Columbia University ‘‘ethical treatment
of research animals’’ guidelines.
Cell Isolation, Culture, Staining, and Sorting
B cells were enriched from mouse splenocytes or peritoneal cavity cells
through CD19 positive selection or CD90.2 negative selection using MACS
(Miltenyi Biotec) columns. B cells were cultured in RPMI-1640 medium con-
taining 10% FBS. 1 mg/ml CD40 antibody, 10 mg/ml LPS, 50 ng/ml PMA,
500 ng/ml ionomycin, and 2 mMmonensin were added as required for specific
experiments. T cells were cultured with or without B cells in RPMI-1640
medium containing 10% FBS with 5 mg/ml CD3e antibody bound to the well
surface of the plate. See Supplemental Experimental Procedures for more
information on cell staining and sorting.
RNA Preparation, qRT-PCR, RNA Expression Profiling, and IPA
Analysis
Total RNA was prepared from isolated B10+ cells and B10– cells. A fraction of
total RNA was used for miRNA analysis (GEO: GSE63374) by hybridization to
microarrays with Sanger miRBase Release 20.0, a fraction for qRT-PCR vali-
dation of RNA-seq, and the remainder was used for further RNA sequencing
(GEO: GSE63426). An independent repeat was performed to enhance the reli-
ability. Reads were mapped to the mouse genome (mm9) and normalized
expression level FPKM (fragments per kilobase of transcript per million map-
ped reads) of known genes and transcripts was obtained. Rank change (RC)
and fold change (FC) of mRNAs between B10+ and B10– cells were analyzed.
The generated list of differentially expressed factors was analyzed by ‘‘Core
Analysis’’ with the IPA (Ingenuity Pathway Analysis) program (QIAGEN)
(Kra¨mer et al., 2014).
The qRT-PCR primer pairs used for coding RNAs were obtained from
PrimerBank (Spandidos et al., 2010), and the primer pairs for noncoding
RNA were designed with DNASTAR Lasergene (Figure S1E).
Ex Vivo B Cell Functional Analysis
VPD450 (BD Biosciences) -stained CD4+CD25– T cells (100 or 2003 103) were
co-cultured with different numbers of autologous CD19+CD9+ B cells or
CD19+CD9– B cells with or without the addition of 10 mg/ml blocking antibody
of CD9 (BioLegend, MZ3 clone) or isotype control. The co-culture was incu-
bated with plate-bound CD3e antibody for 72 hr. Medium was changed at
48 hr. T cell proliferation was detected by dilution of VPD450, and the intracel-
lular IL-10 staining was performed after the cells were stimulated with PMA,
ionomycin, andmonensin for the terminal 5 hr of culture. For assays with trans-
wells (Costar HTS Transwell 96 Well) shown in Figure 4C, VPD450-stained
CD4+CD25– T cells (100 3 103) were seeded in each well of both the receiver
plate and the insert. The insert well was also loaded with different numbers of
autologous CD19+CD9+ B cells or CD19+CD9– B cells. T cell proliferation was
measured after 72 hr in culture.
In Vivo B Cell Functional Analysis
The experiment was performed with mice experiencing an induced CHS
reaction as described (Yanaba et al., 2008). See Supplemental Experimental
Procedures for more information.
Statistics
Statistical significance was determined by Prism software (GraphPad).1116 Cell Reports 13, 1110–1117, November 10, 2015 ª2015 The AuACCESSION NUMBERS
The accession numbers for the RNA-seq and microarray data reported in this
paper are GEO: GSE63426 and GEO: GSE63374.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.09.070.
AUTHOR CONTRIBUTIONS
J.S. and U.B. designed and interpreted all the experiments, E.P. and I.I.I. as-
sisted in designing some of them; J.S. and J.W. performed bioinformatics
analysis with guidance from R.R.; J.S. performed all the experiments, J.C.,
G.R., and J.K.C. assisted in some of them; I.T. and Y.T. provided CD9/
mice; J.S. and U.B. wrote the manuscript.
ACKNOWLEDGMENTS
We thank Dr. Ulf Klein for critically reading the manuscript and Dr. Donna
Farber, Dr. Kang Liu, and Joseph Thome for experimental guidance. This
work was supported by grants from NIH (1DP2OD008651-01) and NIAID
(1R01AI099195-01A1) to U.B. and Trustees of Columbia University faculty
startup funds and the Irma T. Hirschl Charitable Trust (to U.B.). U.B. is a fellow
of the Leukemia and Lymphoma Society of America, J.W. was supported by a
Precision Medicine Initiative Fellowship from Columbia University (UL1
TR000040), and I.I.I. is supported by NIH (R01-DK098378) and CCFA
(SRA#259540) and Pew Charitable trust. J.K.C. was supported by the Inte-
grated Program in Cellular, Molecular and Biomedical Studies.
Received: April 21, 2015
Revised: August 23, 2015
Accepted: September 23, 2015
Published: October 29, 2015
REFERENCES
Blair, P.A., Chavez-Rueda, K.A., Evans, J.G., Shlomchik, M.J., Eddaoudi, A.,
Isenberg, D.A., Ehrenstein, M.R., and Mauri, C. (2009). Selective targeting of
B cells with agonistic anti-CD40 is an efficacious strategy for the generation
of induced regulatory T2-like B cells and for the suppression of lupus in
MRL/lpr mice. J. Immunol. 182, 3492–3502.
Blair, P.A., Noren˜a, L.Y., Flores-Borja, F., Rawlings, D.J., Isenberg, D.A., Eh-
renstein, M.R., and Mauri, C. (2010). CD19(+)CD24(hi)CD38(hi) B cells exhibit
regulatory capacity in healthy individuals but are functionally impaired in sys-
temic Lupus Erythematosus patients. Immunity 32, 129–140.
Cariappa, A., Shoham, T., Liu, H., Levy, S., Boucheix, C., and Pillai, S. (2005).
TheCD9 tetraspanin is not required for the development of peripheral B cells or
for humoral immunity. J. Immunol. 175, 2925–2930.
DiLillo, D.J., Matsushita, T., and Tedder, T.F. (2010). B10 cells and regulatory B
cells balance immune responses during inflammation, autoimmunity, and can-
cer. Ann. N Y Acad. Sci. 1183, 38–57.
Ding, Q., Yeung, M., Camirand, G., Zeng, Q., Akiba, H., Yagita, H., Chalasani,
G., Sayegh, M.H., Najafian, N., and Rothstein, D.M. (2011). Regulatory B cells
are identified by expression of TIM-1 and can be induced through TIM-1 liga-
tion to promote tolerance in mice. J. Clin. Invest. 121, 3645–3656.
Escola, J.M., Kleijmeer, M.J., Stoorvogel, W., Griffith, J.M., Yoshie, O., and
Geuze, H.J. (1998). Selective enrichment of tetraspan proteins on the internal
vesicles of multivesicular endosomes and on exosomes secreted by human
B-lymphocytes. J. Biol. Chem. 273, 20121–20127.
Fatica, A., and Bozzoni, I. (2014). Long non-coding RNAs: new players in cell
differentiation and development. Nat. Rev. Genet. 15, 7–21.thors
Hausser, J., and Zavolan, M. (2014). Identification and consequences of
miRNA-target interactions–beyond repression of gene expression. Nat. Rev.
Genet. 15, 599–612.
Hegmans, J.P., Bard, M.P., Hemmes, A., Luider, T.M., Kleijmeer, M.J., Prins,
J.B., Zitvogel, L., Burgers, S.A., Hoogsteden, H.C., and Lambrecht, B.N.
(2004). Proteomic analysis of exosomes secreted by human mesothelioma
cells. Am. J. Pathol. 164, 1807–1815.
Iwata, Y., Matsushita, T., Horikawa, M., Dilillo, D.J., Yanaba, K., Venturi, G.M.,
Szabolcs, P.M., Bernstein, S.H., Magro, C.M., Williams, A.D., et al. (2011).
Characterization of a rare IL-10-competent B-cell subset in humans that par-
allels mouse regulatory B10 cells. Blood 117, 530–541.
Kalampokis, I., Yoshizaki, A., and Tedder, T.F. (2013). IL-10-producing
regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 15
(Suppl 1), S1.
Karlsson, G., Ro¨rby, E., Pina, C., Soneji, S., Reckzeh, K., Miharada, K., Karls-
son, C., Guo, Y., Fugazza, C., Gupta, R., et al. (2013). The tetraspanin CD9
affords high-purity capture of all murine hematopoietic stem cells. Cell Rep.
4, 642–648.
Kra¨mer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal anal-
ysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523–530.
Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Caldero´n Go´mez, E.,
Sweenie, C.H., Hao, Y., Freitas, A.A., Steinhoff, U., Anderton, S.M., and Filla-
treau, S. (2008). TLR-activated B cells suppress T cell-mediated autoimmu-
nity. J. Immunol. 180, 4763–4773.
Lindner, S., Dahlke, K., Sontheimer, K., Hagn, M., Kaltenmeier, C., Barth, T.F.,
Beyer, T., Reister, F., Fabricius, D., Lotfi, R., et al. (2013). Interleukin
21-induced granzyme B-expressing B cells infiltrate tumors and regulate
T cells. Cancer Res. 73, 2468–2479.
Mann, M.K., Maresz, K., Shriver, L.P., Tan, Y., and Dittel, B.N. (2007). B cell
regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for re-
covery from experimental autoimmune encephalomyelitis. J. Immunol. 178,
3447–3456.
Mauri, C., and Blair, P.A. (2010). Regulatory B cells in autoimmunity: develop-
ments and controversies. Nat. Rev. Rheumatol. 6, 636–643.
Mauri, C., and Bosma, A. (2012). Immune regulatory function of B cells. Annu.
Rev. Immunol. 30, 221–241.
Mauri, C., Gray, D., Mushtaq, N., and Londei, M. (2003). Prevention of arthritis
by interleukin 10-producing B cells. J. Exp. Med. 197, 489–501.
Miyado, K., Yamada, G., Yamada, S., Hasuwa, H., Nakamura, Y., Ryu, F.,
Suzuki, K., Kosai, K., Inoue, K., Ogura, A., et al. (2000). Requirement of CD9
on the egg plasma membrane for fertilization. Science 287, 321–324.
Okoye, I.S., Coomes, S.M., Pelly, V.S., Czieso, S., Papayannopoulos, V.,
Tolmachova, T., Seabra, M.C., and Wilson, M.S. (2014). MicroRNA-containing
T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells.
Immunity 41, 89–103.Cell RepPefanis, E., Wang, J., Rothschild, G., Lim, J., Chao, J., Rabadan, R., Econo-
mides, A.N., and Basu, U. (2014). Noncoding RNA transcription targets AID
to divergently transcribed loci in B cells. Nature 514, 389–393.
Pefanis, E., Wang, J., Rothschild, G., Lim, J., Kazadi, D., Sun, J., Federation,
A., Chao, J., Elliott, O., Liu, Z.P., et al. (2015). RNA exosome-regulated long
non-coding RNA transcription controls super-enhancer activity. Cell 161,
774–789.
Sattler, S., Ling, G.S., Xu, D., Hussaarts, L., Romaine, A., Zhao, H., Fossati-
Jimack, L., Malik, T., Cook, H.T., Botto, M., et al. (2014). IL-10-producing
regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal
inflammatory responses in the gut. J. Autoimmun. 50, 107–122.
Shen, P., Roch, T., Lampropoulou, V., O’Connor, R.A., Stervbo, U.,
Hilgenberg, E., Ries, S., Dang, V.D., Jaimes, Y., Daridon, C., et al. (2014). IL-
35-producing B cells are critical regulators of immunity during autoimmune
and infectious diseases. Nature 507, 366–370.
Spandidos, A., Wang, X., Wang, H., and Seed, B. (2010). PrimerBank: a
resource of human andmouse PCR primer pairs for gene expression detection
and quantification. Nucleic Acids Res. 38, D792–D799.
Stolp, J., Turka, L.A., and Wood, K.J. (2014). B cells with immune-regulating
function in transplantation. Nat. Rev. Nephrol. 10, 389–397.
The´ry, C., Regnault, A., Garin, J., Wolfers, J., Zitvogel, L., Ricciardi-Castagnoli,
P., Raposo, G., and Amigorena, S. (1999). Molecular characterization of den-
dritic cell-derived exosomes. Selective accumulation of the heat shock protein
hsc73. J. Cell Biol. 147, 599–610.
van de Veen, W., Stanic, B., Yaman, G., Wawrzyniak, M., So¨llner, S., Akdis,
D.G., R€uckert, B., Akdis, C.A., and Akdis, M. (2013). IgG4 production is
confined to human IL-10-producing regulatory B cells that suppress anti-
gen-specific immune responses. J. Allergy Clin. Immunol. 131, 1204–1212.
Won, W.J., and Kearney, J.F. (2002). CD9 is a unique marker for marginal zone
B cells, B1 cells, and plasma cells in mice. J. Immunol. 168, 5605–5611.
Yanaba, K., Bouaziz, J.D., Haas, K.M., Poe, J.C., Fujimoto, M., and Tedder,
T.F. (2008). A regulatory B cell subset with a unique CD1dhiCD5+ phenotype
controls T cell-dependent inflammatory responses. Immunity 28, 639–650.
Yanaba, K., Bouaziz, J.D., Matsushita, T., Tsubata, T., and Tedder, T.F. (2009).
The development and function of regulatory B cells expressing IL-10 (B10
cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182,
7459–7472.
Yao, Y., Wei, W., Sun, J., Chen, L., Deng, X., Ma, L., and Hao, S. (2015).
Proteomic analysis of exosomes derived from human lymphoma cells. Eur.
J. Med. Res. 20, 8.
Yoshizaki, A., Miyagaki, T., DiLillo, D.J., Matsushita, T., Horikawa, M., Kounti-
kov, E.I., Spolski, R., Poe, J.C., Leonard, W.J., and Tedder, T.F. (2012). Reg-
ulatory B cells control T-cell autoimmunity through IL-21-dependent cognate
interactions. Nature 491, 264–268.
Zhang, X. (2013). Regulatory functions of innate-like B cells. Cell. Mol. Immu-
nol. 10, 113–121.orts 13, 1110–1117, November 10, 2015 ª2015 The Authors 1117
